stockrowBio-Rad Laboratories, Inc.
BIO Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO
Alert me
Bio-Rad Laboratories, Inc. (BIO) EBITDA
Bio-Rad Laboratories, Inc.'s EBITDA for fiscal 2025 was $47.2M, down 82.5% from $269.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$61.9M. Over the past ten years it has ranged from −$103.3M (fiscal 2018) to $500.3M (fiscal 2021); the current reading is higher than 18% of that period. EBITDA has fallen for 4 consecutive fiscal years. Bio-Rad Laboratories, Inc. ranks 131st of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $47.2M | (82.45%) |
| FY2024 | $269.0M | (20.37%) |
| FY2023 | $337.8M | (30.00%) |
| FY2022 | $482.6M | (3.54%) |
| FY2021 | $500.3M | 18.75% |
| FY2020 | $421.3M | 83.46% |
| FY2019 | $229.7M | — |
| FY2018 | −$103.3M | — |
| FY2017 | $119.3M | 114.02% |
| FY2016 | $55.7M | (66.58%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$49.7M | — |
| Jun 2026 | $72.6M | 112.90% |
| Mar 2026 | $34.1M | — |
| Dec 2025 | −$118.9M | — |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.6B |
| GMED Globus Medical, Inc. compare | $932.9M |
| PODD Insulet Corporation compare | $693.3M |
| PEN Penumbra, Inc. compare | $209.4M |
| BRKR Bruker Corporation compare | $158.7M |
| TXG 10x Genomics compare | −$40.4M |
| BIO.B Bio-Rad Laboratories, Inc. compare | −$61.9M |
| BIO Bio-Rad Laboratories, Inc. | −$61.9M |
| GKOS Glaukos Corporation compare | −$130.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on BIO
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement